Both onartuzumab and bevacizumab are monoclonal antibodies; however, they have different targets (MET and vascular endothelial growth factor, respectively) and, therefore, have different anti-tumor activities and, when combined, can have a stronger anti-tumoral action; however, they can also cause more adverse events. The gene discussed is VEGFA; the disease is neoplasm.